Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
HKSE:08158's Price-to-Median-PS-Value is ranked better than 82.44% of 279
companies
in the Biotechnology industry
Industry Median: 0.62
vs HKSE:08158: 0.26
China Regenerative Medicine International (HKSE:08158) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
China Regenerative Medicine International's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.232
/
0.89
=
0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Median PS Value Related Terms
China Regenerative Medicine International Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Median PS Value Chart
China Regenerative Medicine International Annual Data
HKSE:08158 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Price-to-Median-PS-Value vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International (HKSE:08158) has a Median PS Value of HK$0.89 as of Aug. 08, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Regenerative Medicine International and its competitors. This is 889% above median its historical median of 0.09. Over the past decade, China Regenerative Medicine International's Median PS Value has ranged from 0.01 to 0.67. According to the industry distribution chart, China Regenerative Medicine International ranks #49 out of 279 companies in the Biotechnology industry, placing it in the top 17.6%.
Is China Regenerative Medicine International's Median PS Value too high?
China Regenerative Medicine International's current Median PS Value of HK$0.89 is 889% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.67. Based on the distribution chart, China Regenerative Medicine International ranks #49 out of 279 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #49 out of 279 companies for Median PS Value. This places China Regenerative Medicine International in the top 18% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.62. Historically, China Regenerative Medicine International's own Median PS Value has ranged from 0.01 to 0.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current Median PS Value is HK$0.89, which is 889% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Median PS Value is HK$0.89, which is 889% above median its 10-year median of 0.09. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Median PS Value is HK$0.89 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63.
GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.
Key valuation signals for HKSE:08158:
Median PS Value: HK$0.89 (889% above median its 10-year median of 0.09)
GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for HKSE:08158
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08158 has been successfully added to your 
